ATE284537T1 - Snail, neuer marker für die entwicklung von tumoren und zielprotein neuer antitumoraler verbindungen - Google Patents

Snail, neuer marker für die entwicklung von tumoren und zielprotein neuer antitumoraler verbindungen

Info

Publication number
ATE284537T1
ATE284537T1 AT00938837T AT00938837T ATE284537T1 AT E284537 T1 ATE284537 T1 AT E284537T1 AT 00938837 T AT00938837 T AT 00938837T AT 00938837 T AT00938837 T AT 00938837T AT E284537 T1 ATE284537 T1 AT E284537T1
Authority
AT
Austria
Prior art keywords
new
snail
target protein
marker
tumor development
Prior art date
Application number
AT00938837T
Other languages
English (en)
Inventor
Garcia Amparo Cano
Toledano Maria Angela Nieto
Castro Maria Isabel Rodrigo
Annamaria Locascio
Del Barrio Marta Garcia
Fernandez De Valderrama Blanco
Abascal
Perez Francisco Portillo
Moreno Mirna Alicia Perez
Original Assignee
Consejo Superior Investigacion
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8309058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE284537(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consejo Superior Investigacion, Univ Madrid Autonoma filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE284537T1 publication Critical patent/ATE284537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00938837T 1999-07-01 2000-06-27 Snail, neuer marker für die entwicklung von tumoren und zielprotein neuer antitumoraler verbindungen ATE284537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009901466A ES2161612B1 (es) 1999-07-01 1999-07-01 Procedimiento para identificar un compuesto que inhiba la funcion represora de snail.
PCT/ES2000/000226 WO2001002860A1 (es) 1999-07-01 2000-06-27 Snail, nuevo marcador de progresion tumoral y proteina diana de nuevos compuestos antitumorales

Publications (1)

Publication Number Publication Date
ATE284537T1 true ATE284537T1 (de) 2004-12-15

Family

ID=8309058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00938837T ATE284537T1 (de) 1999-07-01 2000-06-27 Snail, neuer marker für die entwicklung von tumoren und zielprotein neuer antitumoraler verbindungen

Country Status (10)

Country Link
US (6) US6617121B1 (de)
EP (1) EP1109021B1 (de)
AT (1) ATE284537T1 (de)
AU (1) AU5408300A (de)
CA (1) CA2383943A1 (de)
DE (1) DE60016548T2 (de)
DK (1) DK1109021T3 (de)
ES (3) ES2161612B1 (de)
PT (1) PT1109021E (de)
WO (1) WO2001002860A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238055D1 (de) * 2001-06-22 2010-12-02 Burkhard Jansen Verfahren zur diagnose einer person mit multipler sklerose
ES2195751B1 (es) 2001-11-27 2005-04-01 Universidad De Salamanca (Otri) Mamiferos no humanos transgenicos como modelos para patologias humanas con origen en celulas stem.
US20050089896A1 (en) 2003-02-18 2005-04-28 Roy Frans V. Method to control tumor progression and invasiveness
CA2476965A1 (en) * 2002-02-20 2003-08-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method of modulating e-cadherin mediated cell adhesion
WO2004065602A1 (es) * 2003-01-17 2004-08-05 Universidad Autónoma de Madrid Procedimiento para identificar la transición epitelio-mesenquimal de células mesoteliales (temcm) e identificar compuestos moduladores de temcm, composiciones farmacéuticas y su uso en el diagnóstico y tratamiento de enfermedades que cursan con temcm
WO2004086038A2 (en) * 2003-03-28 2004-10-07 Institut Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
US20060003956A1 (en) * 2004-03-03 2006-01-05 Casadome David O Materials and methods for the derepression of the E-cadherin promoter
ES2301268B1 (es) 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2007012970A1 (en) * 2005-07-28 2007-02-01 Oncostem Pharma, S.L. Graded expression of snail as marker of cancer development and dna damage-based diseases
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
JP5240739B2 (ja) * 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
AU2008307579A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694154A1 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
EP2542893A2 (de) * 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN109984062B (zh) * 2018-12-29 2021-07-27 广西桂螺农业科技有限公司 一种厚壳田螺的繁育方法
WO2023126958A1 (en) * 2021-12-30 2023-07-06 Mestastop Solutions Private Limited Method for producing a spontaneous metastasis model

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547432A (en) * 1984-07-31 1985-10-15 The United States Of America As Represented By The United States Department Of Energy Method of bonding silver to glass and mirrors produced according to this method
FR2656129B1 (fr) * 1989-12-20 1992-03-13 Gen Electric Cgr Procede de reconstruction multi-echelle de l'image de la structure d'un corps.
AU2897195A (en) * 1994-07-08 1996-02-09 Frans M. J Debruyne Assay for increased invasiveness of epithelial cells
DE19503510C2 (de) * 1995-02-03 1996-12-19 Sekurit Saint Gobain Deutsch Verfahren zur Herstellung einer IR-reflektierenden Verbundglasscheibe für Kraftfahrzeuge
WO1999020168A2 (en) * 1997-10-17 1999-04-29 University Of Otago Germline mutations in the e-cadherin gene and method for detecting predisposition to cancer
AU4742400A (en) * 1999-09-29 2001-04-30 Ip2H Ag Process for production of a dielectric multi-layered reflecting coating

Also Published As

Publication number Publication date
US20070065450A1 (en) 2007-03-22
ES2234619T3 (es) 2005-07-01
DE60016548D1 (de) 2005-01-13
WO2001002860A1 (es) 2001-01-11
US20070053891A1 (en) 2007-03-08
CA2383943A1 (en) 2001-01-11
EP1109021A1 (de) 2001-06-20
US20070054307A1 (en) 2007-03-08
ES2161655A1 (es) 2001-12-01
US7482159B2 (en) 2009-01-27
ES2161612A1 (es) 2001-12-01
US20040037832A1 (en) 2004-02-26
US7794930B2 (en) 2010-09-14
US6617121B1 (en) 2003-09-09
AU5408300A (en) 2001-01-22
EP1109021B1 (de) 2004-12-08
US20070077590A1 (en) 2007-04-05
US7482126B2 (en) 2009-01-27
ES2161655B1 (es) 2002-06-01
DE60016548T2 (de) 2005-12-08
ES2161612B1 (es) 2002-06-01
PT1109021E (pt) 2005-04-29
DK1109021T3 (da) 2005-03-29

Similar Documents

Publication Publication Date Title
ATE284537T1 (de) Snail, neuer marker für die entwicklung von tumoren und zielprotein neuer antitumoraler verbindungen
DE69933998D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
DE60039353D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
HK1148783A1 (zh) 用於乳房腺的預後的基因表達標記
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
AU7494701A (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
ATE527552T1 (de) Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
DE69942031D1 (de) In prostatakrebs exprimiertes gen
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DE602004011227D1 (de) Injizierbarer komposit für die magnetozytolyse von knochenmetastasezellen
DE10082729D2 (de) Mittel zur Therapie von menschlichen Erkrankungen, insbesondere für die Therapie von Tumoren wie Kolonkarzinomen und Melanomen oder zur Geweberegeneration und Förderung des Haarwuchses
DE60301891D1 (de) Peptid für die Diagnose und Therapie von Tumoren
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
IT1312106B1 (it) Suola o soletta per calzature,particolarmente per la terapia del corpo umano mediante campi magnetici
RU99103901A (ru) Способ медикаментозного лечения злокачественных опухолей
CY1111320T1 (el) Cripto ειδικα αντισωματα

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties